XTALPi and Hansoh Pharma Announce Strategic Collaboration to Develop High-Difficulty Small Molecule Oncology Drugs

Leifeng.com(Official Account: Lei Feng Network)News: Recently, XtalPi announced a strategic partnership with CHIATAI TIANQING, a leading biopharmaceutical company in China. The two parties will collaborate on developing small-molecule drugs targeting high-difficulty sites for the treatment of malignant tumors.

China's biopharmaceutical industry is undergoing profound changes under the dual influence of the policy environment and market environment. Strengthening original innovation and enhancing differentiation levels have become important means for pharmaceutical companies in China to improve competitiveness and ensure future development space.

The collaboration between XtalPi and CHIATAI TIANQING represents a partnership between an emerging biotechnology company centered on artificial intelligence and a large pharmaceutical group integrating research, production, and sales.

In this collaboration, XtalPi will utilize its technical platforms, such as artificial intelligence and high-precision computational chemistry, to complete tasks including compound generation, evaluation, and optimization, with a focus on the discovery and optimization of small-molecule anti-cancer innovative drugs.

Dr. Ma Jian, Co-founder and CEO of XtalPi, said:"The research and development of anti-tumor drugs holds extremely high social value, along with significant technical challenges. Following the release of the National Medical Products Administration’s Guiding Principles for Clinical Research and Development of Anti-Tumor Drugs Oriented by Clinical Value, the market has placed higher demands on the R&D of anti-tumor drugs in China. CHIATAI TIANQING has consistently been at the forefront of the anti-tumor drug R&D field, and we are very pleased to collaborate with CHIATAI TIANQING on this initiative. XtalPi will leverage its intelligent drug discovery platform, combined with CHIATAI TIANQING's robust technical capabilities and project experience, to jointly develop anti-tumor drugs with higher clinical value."

Xie Chengrun, Chairman of Chia Tai Tianqing Pharmaceutical Group Co., Ltd., stated:"Our mission is to provide safe, effective, and accessible drugs for unmet clinical treatment needs through continuous innovation and outstanding work, thereby improving the quality of life. We highly value the use of AI and other cutting-edge technologies to enhance the efficiency of new drug development. XtalPi is a leading company in applying artificial intelligence technology to drug research and development. We believe that through the collaboration of both parties, combining strengths and complementing advantages, we can accelerate the discovery of new drugs targeting difficult anti-tumor targets and develop high-quality cancer treatments."

About XtalPi

XtalPi is a drug research and development company empowered by quantum physics and artificial intelligence. By enhancing the speed, scale, innovation, and success rate of drug R&D, XtalPi is committed to driving industry transformation in pharmaceutical research. As a company based in China and the U.S. while serving the global market, XtalPi consistently explores the most optimal solutions to fully leverage cutting-edge R&D and computational resources, maximizing the satisfaction of clients and partners.

XtalPi's intelligent drug discovery platform integrates cloud-based supercomputing digital R&D tools with advanced experimental capabilities to form a high-precision predictive and targeted experimental system that verifies and guides each other in the R&D process. As one of the global pioneers in AI-driven drug discovery, XtalPi has established a comprehensive iterative R&D process that closely combines quantum physics dry labs with advanced wet labs, challenging the efficiency bottlenecks of traditional R&D and empowering new drug discovery to achieve breakthroughs in speed and scale.

About CHIATAI TIANQING

CHIATAI TIANQING is a leading innovative pharmaceutical group in China that integrates research and development, production, and sales, dedicated to providing patients with high-quality and accessible therapeutic products. As a well-known leader in liver disease drugs in China, the company focuses on meeting public needs by building six key product clusters: liver disease, oncology, respiratory, infectious diseases, endocrinology, and cardiovascular.

CHIATAI TIANQING always regards scientific and technological innovation as the supporting force for the sustainable development of the enterprise. The investment in innovative drug research and development is among the top in the industry, with an annual R&D investment accounting for 12-15% of sales revenue.

Original article by Leifeng.com. Reprinting is prohibited without authorization. For more details, seeReprint Notice。